AI assistant
HAEMONETICS CORP — Director's Dealing 2018
Nov 9, 2018
31565_dirs_2018-11-09_56116f46-d53c-45e8-9f1b-f5541e040704.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2018-11-08
Reporting Person: GRANADILLO PEDRO P (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-11-08 | Common Stock | S | 12322 | $114.50 | Disposed | 15335 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.50 to $114.60, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2: This number includes unvested restricted stock units previously reported.